DekaLux-BioTech TF

Performance History31/03/2024
Growth of 1,000 (EUR)
DekaLux-BioTech TF
Fund14.16.5-7.90.62.4
+/-Cat-5.19.54.9-0.5-1.3
+/-Idx-11.7-0.4-4.8-9.3-7.6
 
Key Stats
NAV
22/04/2024
 EUR 463.44
Day Change 0.13%
Morningstar Category™ Sector Equity Biotechnology
ISIN LU0348461897
Fund Size (Mil)
-
 -
Share Class Size (Mil)
22/04/2024
 EUR 150.94
Max Initial Charge -
Ongoing Charge
19/01/2024
  2.30%
Investment Objective: DekaLux-BioTech TF
N/A
Returns
Trailing Returns (EUR)22/04/2024
YTD-4.92
3 Years Annualised-2.90
5 Years Annualised4.73
10 Years Annualised6.91
12 Month Yield 1.79
Dividend Paying Frequency Annually
Management
Manager Name
Start Date
Not Disclosed
02/06/2008
Inception Date
02/06/2008
Advertisement
Benchmarks
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR EURMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationYes
GrowthYes
IncomeYes
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  DekaLux-BioTech TF31/12/2023
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stocks94.820.0094.82
Bonds0.200.000.20
Cash4.980.004.98
Other0.010.000.01
Top 5 Regions%
United States85.85
Eurozone5.09
United Kingdom4.21
Europe - ex Euro2.70
Asia - Emerging1.17
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare8.88
Regeneron Pharmaceuticals IncHealthcareHealthcare7.17
Amgen IncHealthcareHealthcare6.96
Gilead Sciences IncHealthcareHealthcare6.60
Alnylam Pharmaceuticals IncHealthcareHealthcare3.08
DekaLux-BioTech TF
This fund has performance data calculated prior to the inception date of the fund. This is based upon a simulated/extended track record and is in accordance with Morningstar’s Extended Performance Methodology paper. To find out more about this, click here.
In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookie Settings        Disclosures